Factors Associated with Acute-phase Response of Bisphosphonate-naïve or Pretreated Women with Osteoporosis Receiving an Intravenous First Dose of Zoledronate or Ibandronate

Overview

Journal Osteoporos Int

Specialties Endocrinology
Orthopedics

Date 2017 Mar 17

PMID 28299378

Citations 20

Authors

A W Popp

R Senn

I Curkovic

C Senn

H Buffat

P F Popp

K Lippuner

Affiliations

Soon will be listed here.

Abstract

Introduction: Intravenous (IV) administration of bisphosphonates (BP), such as zoledronate (ZOL) and ibandronate (IBN), may be associated with an APR. The characteristics of APR may differ by compound. The aim of the present study was to evaluate the characteristics of APR (rates, signs and symptoms, severity), in the absence of any preventive measure, after a first IV application of ZOL or IBN in patients naïve or previously exposed to BP in a real-world clinical setting.

Methods: This is an open-label prospective exploratory study with two cohorts of consecutive postmenopausal women with osteoporosis treated with either IV ZOL or IBN at the Department of Osteoporosis of the University Hospital of Berne, Switzerland.

Results: Intravenous BP was administered to 725 women (411 ZOL and 314 IBN). Prior oral or IV BP use was less frequent in the ZOL group (61.8 vs. 71.7%, p = 0.005). In total, 301 women (41.5%) reported the presence of one or more signs or symptoms of APR with rates for ZOL and IBN of 47.7 and 33.4%, respectively (p < 0.001). Corresponding APR rates in the subgroup of BP-naïve patients were 55.6 and 32.4%, respectively (p < 0.001). The leading APR clinical sign was the presence of post-dose myalgia or arthralgia (68.1%). Prior BP exposure was predictive of both APR risk and severity, and lower serum 25-hydroxy vitamin D (25(OH)D) levels were possibly predictive of severity.

Conclusions: In a real-world setting, APR rates with ZOL and IBN may be higher than reported in randomised controlled trials and may differ by compound, prior BP exposure, and serum 25(OH)D levels.

Citing Articles

Persistent Flu-Like Symptoms in a Patient With Glaucoma and Osteoporosis.

Bodnar T Fed Pract. 2024; 41(5):159-162.

PMID: 39398966 PMC: 11468629. DOI: 10.12788/fp.0477.

Preventing OsteoPorosis in Spinal Cord Injury (POPSCI) Study-Early Zoledronic Acid Infusion in Patients with Acute Spinal Cord Injury.

Kumar S, Doyle J, Wood C, Heriseanu R, Weber G, Nier L Calcif Tissue Int. 2024; 115(5):611-623.

PMID: 39320468 PMC: 11531416. DOI: 10.1007/s00223-024-01292-3.

An acute phase reaction from zoledronate mimicking symptoms seen in opioid withdrawal: a case report.

Acharya P, Joseph C Addict Sci Clin Pract. 2024; 19(1):34.

PMID: 38693547 PMC: 11064307. DOI: 10.1186/s13722-024-00464-8.

Optimization of the dosage regimen of zoledronic acid with a kinetic-pharmacodynamic model and exposure-response analysis.

Wang H, Liu Q, Jiang M, Song C, Liu D Front Pharmacol. 2023; 14:1089774.

PMID: 37829305 PMC: 10565503. DOI: 10.3389/fphar.2023.1089774.

Adrenal Crisis as An Adverse Reaction to Zoledronic Acid in a Patient With Primary Adrenal Insufficiency: A Case Report and Literature Review.

Kuo B, Koransky A, Vaz Wicks C AACE Clin Case Rep. 2023; 9(2):32-34.

PMID: 37056413 PMC: 10086596. DOI: 10.1016/j.aace.2022.12.003.

References

Wark J, Bensen W, Recknor C, Ryabitseva O, Chiodo 3rd J, Mesenbrink P . Treatment with acetaminophen/paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zoledronic acid 5 mg. Osteoporos Int. 2011; 23(2):503-12. DOI: 10.1007/s00198-011-1563-8. View

Cosman F, de Beur S, LeBoff M, Lewiecki E, Tanner B, Randall S . Clinician's Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int. 2014; 25(10):2359-81. PMC: 4176573. DOI: 10.1007/s00198-014-2794-2. View

Kanis J, McCloskey E, Johansson H, Cooper C, Rizzoli R, Reginster J . European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2012; 24(1):23-57. PMC: 3587294. DOI: 10.1007/s00198-012-2074-y. View

Black D, Delmas P, Eastell R, Reid I, Boonen S, Cauley J . Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356(18):1809-22. DOI: 10.1056/NEJMoa067312. View

Amin D, Cornell S, Gustafson S, Needle S, Ullrich J, Bilder G . Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J Lipid Res. 1992; 33(11):1657-63. View

Schousboe J, Shepherd J, Bilezikian J, Baim S . Executive summary of the 2013 International Society for Clinical Densitometry Position Development Conference on bone densitometry. J Clin Densitom. 2013; 16(4):455-66. DOI: 10.1016/j.jocd.2013.08.004. View

. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med. 1993; 94(6):646-50. DOI: 10.1016/0002-9343(93)90218-e. View

Delmas P, Adami S, Strugala C, Stakkestad J, Reginster J, Felsenberg D . Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum. 2006; 54(6):1838-46. DOI: 10.1002/art.21918. View

Popp A, Senn C, Franta O, Krieg M, Perrelet R, Lippuner K . Tibial or hip BMD predict clinical fracture risk equally well: results from a prospective study in 700 elderly Swiss women. Osteoporos Int. 2008; 20(8):1393-9. DOI: 10.1007/s00198-008-0808-7. View

10.

Jung A, BISAZ S, Fleisch H . The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals. Calcif Tissue Res. 1973; 11(4):269-80. DOI: 10.1007/BF02547227. View

11.

. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994; 843:1-129. View

12.

Fleisch H . Bisphosphonates--history and experimental basis. Bone. 1987; 8 Suppl 1:S23-8. View

13.

Adami S, Bhalla A, Dorizzi R, Montesanti F, Rosini S, Salvagno G . The acute-phase response after bisphosphonate administration. Calcif Tissue Int. 1987; 41(6):326-31. DOI: 10.1007/BF02556671. View

14.

Russell R, Rogers M, Frith J, Luckman S, Coxon F, Benford H . The pharmacology of bisphosphonates and new insights into their mechanisms of action. J Bone Miner Res. 1999; 14 Suppl 2:53-65. DOI: 10.1002/jbmr.5650140212. View

15.

Reid I, Gamble G, Mesenbrink P, Lakatos P, Black D . Characterization of and risk factors for the acute-phase response after zoledronic acid. J Clin Endocrinol Metab. 2010; 95(9):4380-7. DOI: 10.1210/jc.2010-0597. View

16.

Looker A, Orwoll E, JOHNSTON Jr C, Lindsay R, Wahner H, Dunn W . Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res. 1998; 12(11):1761-8. DOI: 10.1359/jbmr.1997.12.11.1761. View

17.

Thompson K, Rogers M . Statins prevent bisphosphonate-induced gamma,delta-T-cell proliferation and activation in vitro. J Bone Miner Res. 2004; 19(2):278-88. DOI: 10.1359/JBMR.0301230. View

18.

Roelofs A, Jauhiainen M, Monkkonen H, Rogers M, Monkkonen J, Thompson K . Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP. Br J Haematol. 2008; 144(2):245-50. PMC: 2659391. DOI: 10.1111/j.1365-2141.2008.07435.x. View

19.

Silverman S, Kriegman A, Goncalves J, Kianifard F, Carlson T, Leary E . Effect of acetaminophen and fluvastatin on post-dose symptoms following infusion of zoledronic acid. Osteoporos Int. 2010; 22(8):2337-45. PMC: 3132314. DOI: 10.1007/s00198-010-1448-2. View

20.

Hans D, Downs Jr R, Duboeuf F, Greenspan S, Jankowski L, Kiebzak G . Skeletal sites for osteoporosis diagnosis: the 2005 ISCD Official Positions. J Clin Densitom. 2006; 9(1):15-21. DOI: 10.1016/j.jocd.2006.05.003. View